혈액 진단 시장 - 예측(2024-2029년)

The haematology diagnostics market is evaluated at USD6.583 billion for the year 2022, growing at a CAGR of 6.18% to reach the market size of USD10.012 billion by the year 2029.

Haematology is the study of blood and blood-related diseases. The diagnosis of diseases or disorders related to blood, including anemia, blood cancer, and blood clots, among others, comes under the umbrella of haematology diagnostics. The incidences of such blood disorders have been increasing over the past years and are one of the major factors anticipated to drive the haematology diagnostics market growth during the forecast period.

Furthermore, the technological advancements in haematology diagnostics have made it more convenient and efficient. The continuous innovation in the market is expected to augment the market growth further in the coming years as well. Moreover, the growing geriatric population worldwide leads to an increase in the number of patients and is another prominent factor anticipated to boost the demand during the assessment period.

Market Drivers:

• Rising incidences of blood disorders is expected to surge the Haematology Diagnostics Market.

Various kinds of blood disorders are on the rise worldwide, including anemia, hemophilia, blood cancer, and blood clots, among others. Anemia is one such widely prevalent disorder that is increasing its pervasiveness. According to data from the World Bank, the prevalence of anemia among children aged 6-59 months has increased from 10.4% in 2010 to 13.2% in 2019. In Finland, it has increased from 10% in 2010 to 11.8% in 2019, while in Denmark, it reached 14.5% in 2019, rising from 12.6% in 2010.

Furthermore, the data from the World Bank shows that the global prevalence of anemia among women of reproductive age or women aged 15 to 59 years has jumped from 28.5% in 2013 to 29.9% in 2019. Moreover, the cases of blood cancer are increasing at a fast pace, which is expected to propel the haematology diagnostics market growth during the forecast period.

The American Cancer Society states that the estimated new cases of leukemia in the United States in 2021 will be 61,090. It also states that the incidence rate of leukemia in the U.S. has increased from 18 in 2009 to around 20 per 100,000 population in 2017 for males and from 10.8 to 11.8 for females during the same time period. The Leukaemia Foundation in Australia projects the number of blood cancer cases from 110,000 in 2020 to more than 275,000 in 2035.

• Growing geriatric population is anticipated to drive the demand for haematology diagnostics

The global elderly population has been rising over the past years and is projected to further grow in the coming years as well. As the geriatric population ages, the risk of hematological disorders like anemia and leukemia increases. Regular haematological assessments are crucial for early detection and management.

Chronic diseases like cardiovascular diseases and diabetes also impact haematological parameters, making haematology diagnostics essential for monitoring their effects on blood composition and identifying associated complications. In the United States, the share of the elderly population aged 65 and above in the total population has increased from 12.98% in 2010 to 16.63% in 2020, as per the World Bank. China is another country witnessing a rapid rise in its geriatric population.

The population aged 65 and above reached 168.864 billion in the country in 2020, jumping from 108.012 billion in 2010, witnessing a growth of more than 36% over a decade. In France, the population aged 65 and above has surged from 10.958 billion in 2010 to 13.986 billion in 2020, growing by more than 27%. (Source: World Bank)

The population is anticipated to continue to age in the coming years, contributing significantly to the rise in the number of patients. This is anticipated to have a positive impact on the global haematology diagnostics market during the assessment period.

The North American region holds a significant market share

Geographically, the North American region is projected to hold a significant market share owing to the presence of diagnostic centers in abundance. Furthermore, an advanced healthcare system makes it simple for people to get their blood disorders diagnosed and consequently results in a significant market size of haematology diagnostics in the region.

The North American region is projected to witness substantial growth due to improved medical facilities leading to a higher number of people getting access to the needed healthcare services. The rising geriatric population and the overall population are other prominent reasons anticipated to propel the market growth of haematology diagnostics in this region during the forecast period.

North America's advanced healthcare infrastructure, high prevalence of haematological disorders, and rising incidence of chronic diseases drive demand for advanced haematology diagnostics. The region's focus on early diagnosis and monitoring of these conditions drives the demand for haematology diagnostics. Technological advancements in diagnostics, such as automated analyzers and molecular diagnostics, attract healthcare providers to invest in modern solutions. Point-of-care testing is also gaining popularity, contributing to market growth.

Key Developments:

• February 2024- Sysmex Corporation and CellaVision entered a strategic alliance agreement to advance haematology solutions by expanding their portfolio, including next-generation cell morphology analyzers. The partnership began 20 years ago in the field of haematology, which analyzes red, white, and other blood cells. The agreement will extend until 2038 and will utilize Sysmex's expertise in enhancing efficiency and standardization of testing workflow in the haematology field, while maximizing synergies with CellaVision's digital imaging and analysis technologies. The goal is to enhance efficiency and standardization in the testing workflow and improve clinical value in supporting diagnoses.
• August 2023- Abbott received FDA clearance for its Alinity h-series haematology system, allowing laboratories to run complete blood counts (CBC) as part of its Alinity family of diagnostic products. The system includes an automated haematology analyzer and an integrated slide maker and stainer. The Alinity h-series offers a wide array of tests doctors can use to quickly and effectively care for their patients. It offers advantages such as processing up to 119 CBC results per hour, requiring less floor space, and centralized results and control functions.
• July 2023- Sysmex Europe SE introduced the XR-Series, its flagship product line for laboratory haematology. The line builds on the reliability and technology of its predecessor, the XN-Series. It offers new assets and improved throughput to meet laboratory needs. Launched in Japan, the XR-Series incorporates the strengths of customers worldwide. Haematology labs can automate barcode reading, tube sorting, smear management, and reagent management. President and CEO Alain Baverel aim to continue providing reliable diagnostics and services in haematology, stating that the XR-Series is a reliable option for labs.

Key Market Segmentation:

By Test Type

• Hemoglobin
• Blood Count
• Platelet Function
• Hematocrit
• Others

By End-User

• Hospitals and Clinics
• Diagnostic Centers
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• UK
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Processes

3. EXECUTIVE SUMMARY

• 3.1. Key Findings

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis
• 4.5. Analyst View

5. HAEMATOLOGY DIAGNOSTICS MARKET BY TEST TYPE

• 5.1. Introduction
• 5.2. Hemoglobin
  • 5.2.1. Market Opportunities and Trends
  • 5.2.2. Growth Prospects
  • 5.2.3. Geographic Lucrativeness
• 5.3. Blood Count
  • 5.3.1. Market Opportunities and Trends
  • 5.3.2. Growth Prospects
  • 5.3.3. Geographic Lucrativeness
• 5.4. Platelet Function
  • 5.4.1. Market Opportunities and Trends
  • 5.4.2. Growth Prospects
  • 5.4.3. Geographic Lucrativeness
• 5.5. Hematocrit
  • 5.5.1. Market Opportunities and Trends
  • 5.5.2. Growth Prospects
  • 5.5.3. Geographic Lucrativeness
• 5.6. Others
  • 5.6.1. Market Opportunities and Trends
  • 5.6.2. Growth Prospects
  • 5.6.3. Geographic Lucrativeness

6. HAEMATOLOGY DIAGNOSTICS MARKET BY END-USER

• 6.1. Introduction
• 6.2. Hospitals and Clinics
  • 6.2.1. Market Opportunities and Trends
  • 6.2.2. Growth Prospects
  • 6.2.3. Geographic Lucrativeness
• 6.3. Diagnostic Centers
  • 6.3.1. Market Opportunities and Trends
  • 6.3.2. Growth Prospects
  • 6.3.3. Geographic Lucrativeness
• 6.4. Others
  • 6.4.1. Market Opportunities and Trends
  • 6.4.2. Growth Prospects
  • 6.4.3. Geographic Lucrativeness

7. HAEMATOLOGY DIAGNOSTICS MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. By Test Type
  • 7.2.2. By End-User
  • 7.2.3. By Country
    • 7.2.3.1. USA
      • 7.2.3.1.1. Market Opportunities and Trends
      • 7.2.3.1.2. Growth Prospects
    • 7.2.3.2. Canada
      • 7.2.3.2.1. Market Opportunities and Trends
      • 7.2.3.2.2. Growth Prospects
    • 7.2.3.3. Mexico
      • 7.2.3.3.1. Market Opportunities and Trends
      • 7.2.3.3.2. Growth Prospects
• 7.3. South America
  • 7.3.1. By Test Type
  • 7.3.2. By End-User
  • 7.3.3. By Country
    • 7.3.3.1. Brazil
      • 7.3.3.1.1. Market Opportunities and Trends
      • 7.3.3.1.2. Growth Prospects
    • 7.3.3.2. Argentina
      • 7.3.3.2.1. Market Opportunities and Trends
      • 7.3.3.2.2. Growth Prospects
    • 7.3.3.3. Others
      • 7.3.3.3.1. Market Opportunities and Trends
      • 7.3.3.3.2. Growth Prospects
• 7.4. Europe
  • 7.4.1. By Test Type
  • 7.4.2. By End-User
  • 7.4.3. By Country
    • 7.4.3.1. Germany
      • 7.4.3.1.1. Market Opportunities and Trends
      • 7.4.3.1.2. Growth Prospects
    • 7.4.3.2. France
      • 7.4.3.2.1. Market Opportunities and Trends
      • 7.4.3.2.2. Growth Prospects
    • 7.4.3.3. UK
      • 7.4.3.3.1. Market Opportunities and Trends
      • 7.4.3.3.2. Growth Prospects
    • 7.4.3.4. Others
      • 7.4.3.4.1. Market Opportunities and Trends
      • 7.4.3.4.2. Growth Prospects
• 7.5. Middle East and Africa
  • 7.5.1. By Test Type
  • 7.5.2. By End-User
  • 7.5.3. By Country
    • 7.5.3.1. Saudi Arabia
      • 7.5.3.1.1. Market Opportunities and Trends
      • 7.5.3.1.2. Growth Prospects
    • 7.5.3.2. UAE
      • 7.5.3.2.1. Market Opportunities and Trends
      • 7.5.3.2.2. Growth Prospects
    • 7.5.3.3. Others
      • 7.5.3.3.1. Market Opportunities and Trends
      • 7.5.3.3.2. Growth Prospects
• 7.6. Asia Pacific
  • 7.6.1. By Test Type
  • 7.6.2. By End-User
  • 7.6.3. By Country
    • 7.6.3.1. China
      • 7.6.3.1.1. Market Opportunities and Trends
      • 7.6.3.1.2. Growth Prospects
    • 7.6.3.2. India
      • 7.6.3.2.1. Market Opportunities and Trends
      • 7.6.3.2.2. Growth Prospects
    • 7.6.3.3. Japan
      • 7.6.3.3.1. Market Opportunities and Trends
      • 7.6.3.3.2. Growth Prospects
    • 7.6.3.4. South Korea
      • 7.6.3.4.1. Market Opportunities and Trends
      • 7.6.3.4.2. Growth Prospects
    • 7.6.3.5. Taiwan
      • 7.6.3.5.1. Market Opportunities and Trends
      • 7.6.3.5.2. Growth Prospects
    • 7.6.3.6. Thailand
      • 7.6.3.6.1. Market Opportunities and Trends
      • 7.6.3.6.2. Growth Prospects
    • 7.6.3.7. Indonesia
      • 7.6.3.7.1. Market Opportunities and Trends
      • 7.6.3.7.2. Growth Prospects
    • 7.6.3.8. Others
      • 7.6.3.8.1. Market Opportunities and Trends
      • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Bio-Rad Laboratories, Inc.
• 9.2. Boule Diagnostics AB
• 9.3. Abbott Laboratories
• 9.4. Diatron
• 9.5. Biosystems S.A.
• 9.6. F. Hoffmann-La Roche Ltd
• 9.7. Horiba, Ltd.
• 9.8. Erba Diagnostics Mannheim GmbH
• 9.9. Ortho Clinical Diagnostics
• 9.10. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.